Creative Touch Permanent Makeup and Aesthetics

Microbiome-targeted skincare is the applied translation of the bidirectional biology established in the Antimicrobial Peptides parent page and its siblings. The skin microbiome is not a passive surface coating. It is an active immunological partner – Staphylococcus epidermidis inducing hBD-2 through TLR2 signalling, commensal short-chain fatty acids acidifying the surface to restrict KLK5 activity, S. epidermidis lipoteichoic acid suppressing S. aureus Agr quorum sensing – and when that partnership is disrupted by disease, alkaline surfactants, antibiotic overuse, or barrier dysfunction, the skin loses immune capabilities it cannot replace from within its own cells alone.

What makes this category genuinely distinct from conventional skincare is its mechanism. A moisturiser repairs the barrier by adding lipids. A microbiome-targeted ingredient changes the microbial ecosystem so the skin’s own innate immunity functions better. That is not a cosmetic mechanism – it is an immunological one, operating through TLR2 pattern recognition, NF-κB-driven hBD-2 transcription, and pH-mediated competitive ecology. The distinction matters for how these ingredients are positioned in UK clinical and commercial contexts, where that immunological framing carries both greater clinical credibility and greater regulatory scrutiny.

Why the microbiome is a clinical target

The human skin surface supports approximately 10¹² microorganisms across 1.8m² – a density and diversity that varies by anatomical site, age, hormonal status, and skin condition. The sebaceous face and trunk are dominated by lipid-metabolising Cutibacterium species; the moist folds by Staphylococcus species; the dry forearms and legs by a more diverse mixed ecology including Corynebacterium, Micrococcus, and Propionibacterium genera. This is not contamination. It is a co-evolved ecosystem that the skin’s immune architecture is designed to work with. ^[4]

The clinical case for targeting this ecosystem rests on three mechanistic foundations established throughout this knowledge base:

The commensal-AMP circuit. S. epidermidis – the dominant commensal of sebaceous skin – produces lipoteichoic acid and lipoproteins that ligate TLR2 on keratinocytes, driving NF-κB activation and hBD-2 transcription continuously at homeostatic colonisation densities. The hBD-2 produced through this circuit is active against S. aureus while S. epidermidis itself has co-evolved tolerance to it – making the commensal an active participant in its own competitive advantage over the pathogen. When S. epidermidis diversity collapses in AD-affected skin, this TLR2/hBD-2 circuit underperforms, and S. aureus colonisation follows directly. Microbiome-targeted skincare that supports S. epidermidis is therefore supporting hBD-2 production indirectly – through the microbiome rather than through direct keratinocyte stimulation. ^[7]

The acid mantle as ecological management. The skin surface pH of 4.5–5.5 maintained by commensal metabolic activity – lactic acid, short-chain fatty acids, propionic acid from fermentation of skin surface glycerol and carbohydrate – creates the acidic microenvironment that S. epidermidis tolerates and S. aureus does not. When this pH is elevated by alkaline surfactants, hard water mineral deposition, or barrier dysfunction, the ecological advantage reverses: S. aureus colonisation increases, S. epidermidis density decreases, TLR2-driven hBD-2 falls, and KLK5 activity increases as the pH gating mechanism described in the KLK5 entity loses its regulatory precision. The acid mantle is, among other things, a microbiome-maintained feature of healthy skin. Disrupting it is disrupting both the ecology and the KLK5 regulatory system simultaneously. ^[4]

Quorum sensing suppression. S. aureus uses the Agr (accessory gene regulator) quorum sensing system to coordinate virulence – switching from adhesive, biofilm-forming behaviour at low density to toxin production, protease secretion, and immune evasion at high density. LL-37 at concentrations maintained by healthy skin suppresses Agr quorum sensing in S. aureus below the threshold required for virulence factor expression – keeping S. aureus in a behavioural state that does not damage the barrier or trigger innate immune cascades. This suppression fails when LL-37 is deficient, as in AD. Microbiome management strategies that maintain the commensal ecology supporting LL-37 production are therefore indirectly maintaining Agr suppression in S. aureus – a mechanistic chain from product formulation to pathogen behaviour. ^[11]

The four-category framework

Microbiome-targeted skincare products divide into four mechanistic categories that differ in what they contain, how they act, and what evidence standard applies to each:

Prebiotics – substrates that selectively support the growth or metabolic activity of beneficial microorganisms at the skin surface without being equally exploited by pathogens. The selectivity is the critical feature: a compound that supports all bacteria equally is not a prebiotic. In skin, the best-characterised prebiotics are complex carbohydrates – inulin and fructooligosaccharides (FOS) among the most studied – that S. epidermidis ferments preferentially through its carbohydrase enzyme repertoire, producing short-chain fatty acids (SCFAs), primarily acetic and isovaleric acid, that acidify the local skin surface and contribute directly to acid mantle maintenance. A 2024 comparative study confirmed that FOS demonstrates the strongest selective effect among four oligosaccharides tested – promoting S. epidermidis CCSM0287 proliferation and SCFA production while the post-fermentation supernatant significantly inhibited S. aureus biofilm formation. S. aureus lacks the equivalent carbohydrase pathways to exploit the same substrates at comparable efficiency – the selectivity is metabolic, not antimicrobial. ^[10]

Postbiotics – defined by the International Scientific Association of Probiotics and Prebiotics (ISAPP) 2021 consensus as “a preparation of inanimate microorganisms and/or their components that confers a health benefit on the host.” The term inanimate is deliberate – chosen over inactive to capture the fact that the organism was living and has been killed, without implying loss of function. In skin, the postbiotic category includes heat-inactivated bacterial lysates, bacterial cell wall fragments, fermentation filtrates, and purified microbial metabolites. Commercially, it is the most prevalent microbiome-targeted format in cosmetics – a heat-inactivated lysate delivers the same TLR2-activating cell wall components as the live organism without the sterility, formulation stability, and shelf-life requirements that live bacteria demand. Vitreoscilla filiformis lysate is the most mechanistically characterised skin postbiotic, with direct hBD-2 induction data and RCT clinical evidence. ^[9]

Probiotics – live or viable microorganisms intended to confer benefit when applied to the skin surface. This is the most complex category for topical application. Maintaining bacterial viability through conventional formulation processes – emulsifiers, preservative systems, oxidative exposure, temperature variation across supply chain – is a significant technical challenge. A 2025 Nature Scientific Reports study on skin microbiome-friendly topical formulations containing probiotics confirmed that physicochemical parameters including pH, viscosity, and moisture content require precise management to maintain probiotic viability; stabilised spore-forming organisms tolerate formulation conditions more readily than vegetative cells. In the UK regulatory context, a topical product containing live bacteria and making a pharmacological or immunological claim – modifying TLR2 signalling or inducing hBD-2 – risks MHRA borderline classification as a medicine rather than a cosmetic, carrying substantially higher evidence and licensing requirements. Products in this space tend to either use spore-forming organisms, keep claims within established cosmetic function language, or opt for the postbiotic lysate approach to deliver equivalent TLR2 agonism without live organism regulatory exposure. ^[12]

Synbiotics – combinations of prebiotics and postbiotics (or probiotics) in the same formulation, designed to provide both ecological substrate support and direct innate immune stimulation simultaneously. The rationale is sequential and complementary: the postbiotic component provides the immediate TLR2/hBD-2 induction signal at every application; the prebiotic supports the commensal ecosystem between applications so the natural TLR2 circuit gradually re-establishes as S. epidermidis density recovers. SCFAs produced by commensal fermentation of the prebiotic component additionally reinforce the barrier and modulate keratinocyte differentiation – butyrate in particular facilitating keratinocyte differentiation and enhancing tight junction protein expression independently of the TLR2 pathway. ^[6]

UK regulatory context

The UK Cosmetic Products Regulation (retained EU Reg 1223/2009, as amended) does not categorically prohibit live microorganisms in cosmetic products – but the mechanism-of-action framing determines whether a product remains a cosmetic or crosses into borderline medicine territory under MHRA classification. ^[2]

The critical distinction is between: Cosmetic function claims – “supports skin’s natural microbiome balance,” “maintains skin’s natural defences,” “promotes a healthy-looking complexion” – these remain within cosmetic territory and do not require medicine licensing Pharmacological/immunological claims – “activates TLR2 signalling,” “induces beta-defensin production,” “modifies innate immune response” – these risk triggering MHRA borderline classification as a medicine, requiring a Product Licence

In practice, the most scientifically accurate framing of microbiome-targeted ingredients is precisely the framing that risks borderline classification – because the mechanism is genuinely immunological. For clinical knowledge base content and internal training materials, the mechanistic accuracy is appropriate and necessary. For patient-facing claims and marketing materials, the language requires translation into cosmetic function framing that is accurate but regulatory-compliant.

The ASA/CAP guidance (updated February 2026) requires that specific efficacy claims for cosmetic products can be substantiated with appropriate evidence – and “microbiome” claims have been flagged as an area of increased monitoring interest. Products citing specific clinical studies in their marketing are held to the standard of those studies – which means the distinction between V. filiformis RCT data and inulin in vitro data matters commercially as well as scientifically. ^[1]

Evidence landscape

Not all ingredients in this category are equally evidenced.

Tier 1 – Clinical trial evidence with mechanistic characterisation: Vitreoscilla filiformis lysate: 75-patient double-blind RCT with significant SCORAD, TEWL, pruritus, S. aureus colonisation density, and sleep quality improvement at 30 days; TLR2/PKCζ/hBD-2 mechanism characterised in keratinocyte models; spa water-grown variant (LRP-VFB) demonstrating 4–6× hBD-2 amplification over standard lysate in direct comparative testing. The strongest evidence package in the category. ^[3]

Tier 2 – Mechanistic evidence with supporting in vitro and ex vivo data: Inulin and fructooligosaccharides: confirmed selective S. epidermidis CCSM0287 support over S. aureus in a 2024 primary Int J Cosmet Sci comparative study of four oligosaccharides – FOS demonstrating the strongest effect, promoting S. epidermidis growth, increasing SCFA production, and generating fermentation supernatant with significant S. aureus biofilm inhibition activity. Mechanistic rationale further supported in a 2025 PMC prebiotic oligosaccharides review incorporating animal studies and clinical trial data showing topical oligosaccharide application alleviating AD and enhancing skin hydration through microbiota modulation. No standalone topical inulin RCT at the time of writing – clinical claims should be made at the mechanism level. ^[10]

Tier 3 – Commercial presence with supporting mechanistic data: Lactobacillus ferment lysate: a 2023 J Cosmet Dermatol clinical study of ferment lysates of Lacticaseibacillus rhamnosus IDCC 3201 (Cera-Glow) demonstrated improved skin barrier function clinically, following in vitro evidence that the same ferment lysate enhances ceramide production in human epidermal keratinocytes. Broad commercial presence under the generic INCI “Lactobacillus Ferment” reflects variable formulations from different fermentation sources – the ceramide stimulation and barrier protein upregulation data is specific to characterised lysate preparations, not universal to the ingredient name across all formulations. Weaker TLR2/AMP induction specificity than Tier 1 and 2 ingredients; clinically relevant primarily for barrier support and general microbiome-supportive action. ^[8]

Tier 4 – Emerging, preclinical: Bacteriophage therapies targeting S. aureus or C. acnes with phage specificity; S. epidermidis-based competitive exclusion approaches – a 2025 Frontiers in Immunology review confirmed that topical application of S. aureus-inhibiting commensal coagulase-negative staphylococci strains has reduced S. aureus load in vivo in AD patients, and that these strains are specifically rare in AD skin; synthetic postbiotics mimicking TLR2-active cell wall components. Each has genuine scientific rationale and emerging clinical signal; none yet has sufficient evidence for routine product recommendation. ^[4]